Latest Breaking News On - Therapeutics targets - Page 1 : comparemela.com

argenx SE: argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

argenx SE: argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNoord hollandMjamesf howardGil wolfeDemyelinating polyneuropathyYuebing liA gordon smithPushpa narayanaswamiGlenn phillipsCynthia qiLuc truyenTom hughesBen petokJamesf howard jrAntoine azar

Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia.

United kingdomNoord hollandUnited statesDemyelinating polyneuropathyTom hughesA gordon smithYuebing liGil wolfeRichard lewisBen petokLuc truyenJamesf howard jrGlenn phillipsTuan vuPushpa narayanaswamiKelly gwathmey

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini.

Noord hollandUnited statesUnited kingdomPushpa narayanaswamiCynthia qiJamesf howard jrRichard lewisMjamesf howardLuc truyenGil wolfeTuan vuBen petokAntoine azarTom hughesYuebing liA gordon smith

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis - argenx (NASDAQ:ARGX)

VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated patients were responders

United statesNoord hollandUnited kingdomErin murphyStacey linternHealth canadaUniversity of torontoImmunology innovation programDivision of neurologyUniversity health networkVera brilNeuromuscular sectionUniversity healthChief executive officerMuscular dystrophyNorth america

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for ...

VYVGARTⓇis the first-and-only neonatal Fc receptor (FcRn) blockerauthorized for salein CanadaApproval based on thepositivePhase 3 ADAPTtrial(p<0.0001)showing68% ofVYVGART-treatedpatients wereresponders on the MG-ADL scale compared to 30% of placebo patients after one

Noord hollandStacey linternErin murphyHealth canadaUniversity of torontoUniversity health networkDivision of neurologyVera brilNeuromuscular sectionUniversity healthChief executive officerMuscular dystrophyTherapeutics targetsAutoimmune myastheniaClinical trials